title: Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
abstract: HMG-CoA reductase inhibitors (statins) are the drugs of first choice for treating hypercholesterolaemia in order to prevent or slow the progression of coronary heart disease (CHD). Statins generally reduce the risk of CHD morbidity or mortality by about 30%. Lovastatin is effective in lowering plasma total cholesterol and low-density lipoprotein cholesterol levels, and is widely prescribed for both the primary and secondary prevention of CHD. In the major AFCAPS/TexCAPS primary prevention study of 6605 middle-aged or elderly men and women without symptomatic cardiovascular disease and with only moderately elevated serum lipids, treatment with lovastatin 20-40 mg once daily for a mean of 5.2 years significantly (p < 0.001) reduced the incidence of a first acute major cardiac event by 37% compared with placebo. In the smaller ACAPS study of 919 men and women who were asymptomatic for cardiovascular disease, but with evidence of early atherosclerosis, treatment with lovastatin for 3 years significantly (p = 0.001) slowed or reversed atherosclerosis compared with placebo, as measured by changes in the intimal-medial thickness of carotid arteries on B-mode ultrasound. Three randomised, controlled, secondary prevention trials have demonstrated that in patients with coronary artery disease, treatment with lovastatin 20-80 mg/day alone or in combination with colestipol for 2-2.5 years reduced the severity of stenosis and/or slowed or reversed the progression of atherosclerosis, as assessed by angiography. In the FATS study, the severity of stenosis after 2.5 years in recipients of lovastatin plus colestipol was reduced by 2.8% compared with placebo, while the frequency of lesion progression was halved and the frequency of lesion regression was tripled. Treatment with lovastatin for 2.2 years in the MARS study significantly reduced the mean percent diameter stenosis compared with placebo (p = 0.005) in patients with more severe stenosis, and also significantly (p = 0.002) reduced the mean global change score (indicating less progression). In the CCAIT study, lovastatin therapy for 2 years significantly improved coronary change scores (p < 0.01) and significantly reduced the incidence of new lesions (p = 0.001) compared with placebo. Across the primary and secondary prevention studies, lovastatin was shown to be similarly effective in women, the elderly, smokers and in subjects with hypertension, hypercholesterolaemia or type 2 diabetes mellitus. Therefore, the available data demonstrate that lovastatin provides significant lipid-modifying efficacy, slows progression or causes regression of atherosclerosis, and protects against acute cardiac events, in both those with and those without symptomatic CHD.
authors: Divisione di Cardiologia Riabilitativa, Presidio Ospedaliero di Passirana, AO G. Salvini, Garbagnate Milanese, Milan, Italy. annafris@tin.it
authors: Anna
authors: A
authors: Frisinghelli
authors: Antonio
authors: A
authors: Mafrici
mesh_terms: D000328:Adult; D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin
references: CMAJ. 2005 Apr 26;172(9):1187-94
references: 15851712
references: Am J Cardiol. 2000 Dec 1;86(11):1176-81
references: 11090787
references: Am J Cardiol. 2001 May 1;87(9):1074-9
references: 11348605
references: Clin Cardiol. 1996 Sep;19(9):683-9
references: 8874986
references: Circulation. 1996 Aug 15;94(4):614-21
references: 8772679
references: N Engl J Med. 2001 Jun 28;344(26):1959-65
references: 11430324
references: Am J Manag Care. 1997 Oct;3(10):1537-45
references: 10178460
references: JAMA. 1998 May 27;279(20):1615-22
references: 9613910
references: J Womens Health Gend Based Med. 2001 Dec;10(10):971-81
references: 11788107
references: J Am Coll Cardiol. 1998 Sep;32(3):665-72
references: 9741509
references: Am J Cardiol. 1998 Mar 1;81(5):582-7
references: 9514454
references: JAMA. 2007 Mar 28;297(12 ):1344-53
references: 17384434
references: Presse Med. 1999 Nov 20;28(36):2002-10
references: 10599269
references: Am J Cardiol. 1991 Mar 1;67(6):447-53
references: 1998274
references: JAMA. 2004 Mar 3;291(9):1071-80
references: 14996776
references: Circulation. 1999 Jan 19;99(2):237-42
references: 9892589
references: Am J Cardiol. 1990 Sep 18;66(8):44B-55B
references: 2206036
references: Circulation. 2002 Dec 17;106(25):3143-421
references: 12485966
references: Clin Ther. 2006 Jan;28(1):26-35
references: 16490577
references: BMJ. 2000 Mar 11;320(7236):705-8
references: 10710586
references: N Engl J Med. 1990 Nov 8;323(19):1289-98
references: 2215615
references: Arch Intern Med. 1991 Jan;151(1):43-9
references: 1985608
references: N Engl J Med. 2005 Apr 7;352(14):1425-35
references: 15755765
references: Ann Intern Med. 1996 Mar 15;124(6):548-56
references: 8597317
references: Curr Opin Cardiol. 2002 Sep;17(5):503-11
references: 12357127
references: Diabetes Metab Rev. 1987 Apr;3(2):463-524
references: 3552530
references: Circulation. 1994 Oct;90(4):1679-87
references: 7734010
references: Circulation. 2001 Mar 6;103(9):1191-3
references: 11238259
references: Circulation. 1995 Nov 1;92 (9):2404-10
references: 7586338
references: JAMA. 2001 May 16;285(19):2481-5
references: 11368701
references: Arch Intern Med. 1993 May 10;153(9):1079-87
references: 8481075
references: BMJ. 2000 Jul 22;321(7255):199-204
references: 10903648
references: Circulation. 1994 Jul;90(1):42-9
references: 8026027
references: JAMA. 2006 Apr 5;295(13):1556-65
references: 16533939
references: Circulation. 1994 Mar;89(3):959-68
references: 8124836
references: Immunol Res. 2002;25(3):271-85
references: 12018465
references: Optom Vis Sci. 1993 Nov;70(11):937-43
references: 8302530
references: Ann Intern Med. 1996 Dec 15;125(12):990-1000
references: 8967711
references: Am J Cardiol. 1988 Nov 11;62(15):44J-49J
references: 3055923
references: Arzneimittelforschung. 2003;53(9):605-11
references: 14558433
references: Am Heart J. 1999 Aug;138(2 Pt 2):S177-82
references: 10426879
references: Am Heart J. 2000 Apr;139(4):577-83
references: 10740137
references: N Engl J Med. 2004 Apr 8;350(15):1495-504
references: 15007110
references: Am J Med. 1991 Jul 31;91(1B):25S-30S
references: 1831006
references: Exp Eye Res. 1990 Jan;50(1):65-78
references: 2307197
references: BMJ. 2003 Jun 28;326(7404):1423
references: 12829554
references: Circulation. 1999 Jul 20;100(3):230-5
references: 10411845
references: N Engl J Med. 1997 Apr 3;336(14):973-9
references: 9077376
references: N Engl J Med. 2000 Mar 23;342(12):836-43
references: 10733371
references: Curr Opin Lipidol. 2001 Aug;12(4):391-4
references: 11507323
references: Am J Med. 1991 Jul 31;91(1B):18S-24S
references: 1867232
references: Am J Cardiol. 1998 Aug 27;82(4B):3J-10J
references: 9737640
references: N Engl J Med. 1988 Jan 14;318(2):81-6
references: 3422105
references: Ann Intern Med. 1993 Nov 15;119(10 ):969-76
references: 8214993
references: Am J Cardiol. 1995 Sep 28;76(9):47C-53C
references: 7572686